Haleon cancels over 10 million shares in ongoing buyback programme

An update from Haleon PLC ( (GB:HLN) ) is now available.

Haleon has continued executing its previously announced share buyback programme, purchasing 10,205,329 ordinary shares for cancellation across multiple trading venues between 5 and 8 May 2026. Following these transactions, the company’s registered share capital stands at 8,880,262,266 shares, of which 12,184,020 are held in treasury, leaving 8,868,078,246 shares with voting rights, a change that may influence ownership disclosures and earnings-per-share metrics.

The most recent analyst rating on (GB:HLN) stock is a Buy with a £400.00 price target. To see the full list of analyst forecasts on Haleon PLC stock, see the GB:HLN Stock Forecast page.

Spark’s Take on HLN Stock

According to Spark, TipRanks’ AI Analyst, HLN is a Neutral.

The score is driven primarily by solid financial performance (consistent free cash flow and improving profitability) and a cautiously positive earnings outlook supported by margin gains and cost savings. This is tempered by weaker near-term technical momentum and only moderate valuation support.

To see Spark’s full report on HLN stock, click here.

More about Haleon PLC

Haleon plc is a global consumer health company focused on improving everyday health through branded over-the-counter products. Its portfolio spans oral health, vitamins, minerals and supplements, pain relief, respiratory and digestive health, and therapeutic skin care, with well-known brands such as Advil, Panadol, Sensodyne, Centrum and Voltaren reaching more than a billion consumers worldwide.

Average Trading Volume: 23,598,233

Technical Sentiment Signal: Sell

Current Market Cap: £29.4B

See more insights into HLN stock on TipRanks’ Stock Analysis page.